The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

BTG PLC granted Carrick Therapeutics Ltd. exclusive global rights to BTG945 for ovarian cancer. Financial terms were not disclosed.

Carrick renamed the project CT900. The small-molecule candidate selectively enters cells that overexpress folate receptor alpha and inhibits thymidylate synthase, causing cancer cell death while sparing surrounding healthy tissue. It has shown positive results in studies of platinum-resistant/refractory high-grade serous ovarian cancer, and Carrick intends to study it for additional hard-to-treat tumors as well. Three-year-old Carrick will develop CT900 alongside CT7001, a CDK inhibitor in Phase I, and other preclinical candidates. The company emerged from stealth mode in late 2016 with a $95mm Series A round from investors including Arch Venture Partners, Woodford Investment Management, Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec, GV (Google Ventures), and Lightstone Ventures.


+ Show All | – Hide All

Financials

There are no financials available.

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Pharmaceuticals
Deal Status Final
Deal Type Alliance
R+D and Marketing-Licensing
Latest Phase at Time of Deal Clinical Development
Phase I

Product Information


Click a keyword for comparable deals.

Product 1 of 1
Product Type Pharmaceutical
Lab Code CT900
BTG945
Mechanism of Action Folate receptor antagonist
Thymidylate synthase inhibitor
Highest Phase at Time of Deal Clinical Development
Phase I
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Reproductive System Cancer
Ovarian Cancer
Licenser Name BTG PLC
Clinical Developer Carrick Therapeutics Ltd.
Licensee Name Carrick Therapeutics Ltd.
Carveouts for Carrick Therapeutics Ltd.
Territories Licensed Worldwide (All) (Exclusive)

Company Information


Click a keyword for comparable companies.

BTG PLC www.btgplc.com | Ticker: BGC
View Company Profile | View Company Deals
Company Location Worldwide
Europe
Western Europe
UK
Industry Medical Devices
Implantable Devices
Pharmaceuticals
Drug Delivery
Site Specific
Ownership Public
Therapeutic Area(s) of Focus Non-Specific
Alias(es) British Technology Group
Revenue $314.95mm

Carrick Therapeutics Ltd. www.carricktherapeutics.com
View Company Profile | View Company Deals
Company Location Worldwide
Europe
Western Europe
Ireland
Industry Biotechnology
Pharmaceuticals
Description Start-Up
Ownership Private
Therapeutic Area(s) of Focus Cancer
Alias(es) Navillus Therapeutics